

Company registration number: **06354157**

Ray Pharm Ltd
Unaudited Filleted Financial Statements for the
year ended
31 August 2017

Ray Pharm Ltd

Report to the director on the preparation of the unaudited statutory financial statements of Ray Pharm Ltd

Year ended 31 August 2017

As described on the statement of financial position, the Board of Directors of Ray Pharm Ltd are responsible for the preparation of the financial statements for the year ended 31 August 2017, which comprise the income statement, statement of financial position and related notes.

You consider that the company is exempt from an audit under the Companies Act 2006.

In accordance with your instructions I have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and from information and explanations supplied to me.

Company Formations London Ltd

Unit A

5 Colville Road

Acton, London

London

W3 8BL

United Kingdom

Ray Pharm Ltd

Statement of Financial Position

31 August 2017

		2017	2016
	Note	£	£
CURRENT ASSETS			
Debtors	4	431,570	66,761
Cash at bank and in hand		1,095,879	1,224,474
		1,527,449	1,291,235
Creditors: amounts falling due within one year	5	(1,688,668)	(1,298,356)
Net current liabilities		(161,219)	(7,121)
Total assets less current liabilities		(161,219)	(7,121)
CAPITAL AND RESERVES			
Called up share capital		2	2
Profit and loss account		(161,221)	(7,123)
Shareholders deficit		(161,219)	(7,121)

For the year ending 31 August 2017, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered.

These financial statements were approved by the board of directors and authorised for issue on 8 January 2018, and are signed on behalf of the board by:

Stylianos Stylianou

Director

Company registration number: 06354157

Ray Pharm Ltd

Notes to the Financial Statements

Year ended 31 August 2017

1 GENERAL INFORMATION

The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is 7/11 Minerva Road, London, NW10 6HJ, United Kingdom.

2 STATEMENT OF COMPLIANCE

These financial statements have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable to the UK and Republic of Ireland'.

3 ACCOUNTING POLICIES

BASIS OF PREPARATION

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain assets.

The financial statements are prepared in sterling, which is the functional currency of the company.

TURNOVER

Turnover is measured at the fair value of the consideration received or receivable for goods supplied, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

FINANCIAL INSTRUMENTS

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price and are subsequently measured as follows: Debt instruments are subsequently measured at amortised cost and commitments to receive a loan and to make a loan to another entity are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value

with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

All other financial instruments, including derivatives, are initially recognised at fair value, which is normally the transaction price and are subsequently measured at fair value, with any changes recognised in profit or loss.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

All equity instruments regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4 DEBTORS

	2017	2016
	£	£
Other debtors	431,570	66,761

5 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2017	2016
	£	£
Trade creditors	1,122,171	893,605
Other creditors	566,497	404,751
	1,688,668	1,298,356

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.